Synthetic oligonucleotides: Useful molecules? A review

Pharmacy World and Science

Volumn 19, Issue 6, 1997, Pages 264-268

  Calogero, Anna ^a   Hospers, Geke A P ^a   Mulder, Nanno H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antigene strategy; Antisense oligonucleotides; Antisense strategy; Oncogenes; Ribozymes

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

BLOOD BRAIN BARRIER; CANCER; DNA SYNTHESIS; DRUG DESIGN; DRUG DEVELOPMENT; DRUG STABILITY; GENE EXPRESSION; GENE TRANSFER; HUMAN; NONHUMAN; REVIEW; RNA SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; OLIGONUCLEOTIDES;

EID: 0030772956     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008699515124     Document Type: Review

References (20)

1. Scanlon KJ, Ohta Y, Ishida H, Kjima H, Ohkawa T, Kaminski A et al. Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 1995;9:1288-96.
2. Stein CA. Antitumor effects of antisense phosphorothioate cmyc oligodeoxynucleotides: a question of mechanism. J Natl Cancer Inst 1996;88:391-3.
3. McShan WM, Rossen RD, Laughter AH, Trial J, Kessler DJ, Zendegui JG et al. Inhibition of transcription of HIV-1 in infected human cells by oligodeoxynucleotides designed to form DNA triple helices. J Biol Chem 1992;267:5712-21.
4. Kashani-Sabet M, Scanlon K. Application of ribozymes to cancer gene therapy. Cancer Gene Ther 1995;2:213-23.
5. Quattrone A, Di Pasquale G, Capaccioli S. Enhancing antisense oligonucleotide intracellular levels by means of cationic lipids as vectors. Biochemica 1995;1:25-9.
6. Crooke ST. Progress in antisense therapeutics. Hematol Pathol 1995;9:59-72.
7. Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF. Antisense oligonucleotides inhibit ICAM-1 expression by two distinct mechanisms. J Biol Chem 1991;266:18162.
8. Kuramoto E, Yano O, Kimura Y, Baba M, Makino T, Yamamoto S, Yamamoto T, Kataoka T, Tokunaga T. Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res 1992;83:1128.
9. Psietsky DS, Reich CF. Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sciences 1993;3:391.
10. Slavkin HC. Antisense oligonucleotides: an experimental strategy to advance a casual analysis of development, Int J Dev Biol 1995;39:123-6.
11. Lefebvre-d'Hellencourt C, Diaw L, Guenounou M. Immunomodulation by cytokine antisense oligonucleotides. Eur Cytokine Netw 1995;6:7-19.
12. Pan Y-X, Cheng J, Xu J, Rossi G, Jacobson E, Ryan-Moro J et al. Cloning and functional characterization through antisense mapping of k3-related opioid receptor. Mol Pharmacol 1995;47:1180-8.
13. Sun LQ, Pyati J, Smythe J, Wang L, Macpherson J, Gerlach W et al. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric transactivation response element constructs. Proc Natl Acad Sci USA. 1995;92:7272-6.
14. Tan TMC, Ting RCY. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res 1994;15:4599-605.
15. Neurath MF, Pettersson S, Meyer zum Buchenfelde K-H, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kB abrogates established experimental colitis in mice. Nature Med 1996;2:998-1004.
16. Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G et al. Antitumor effect of c-myc antisense phosphorothioate oligonucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 1996;88:419-29.
17. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med 1996;2:668-75.
18. Kiehntopf M, Brach MA, Licht T, Petschauer S, Karawajew L, Kirschning C et al. Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J 1994;13:4645-52.
19. Bishop MR, Bayever E, Iversen PL, Sharp G, Spinolo J, Zon G et al. Phase I trial of systemic administration of OL(1)p53 oligonucleotide in refractory acute myelogenous leukemia and advanced myelodysplastic syndrome. Blood 1993;82 Suppl 1:443a.
20. Roth JA. Gene replacement strategies for cancer. Israel J Med Sci 1996;32:89-94.